Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance (Q36577029)

15 August 2017

1 reference

title

Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance (English)

1 reference

15 August 2017

0 references

1 reference

Michael Roden

1

1 reference

15 August 2017

1 June 2006

1 reference

Nature Clinical Practice Endocrinology and Metabolism

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

6

1 reference

15 August 2017

335-348

1 reference

Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Clinical aspects of fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Hepatic glucose metabolism in humans--its role in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

The role of lipid accumulation in liver and muscle for insulin resistance and type 2 diabetes mellitus in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Splanchnic lipolysis in human obesity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Lipid overload and overflow: metabolic trauma and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Mitochondrial dysfunction and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

How obesity causes diabetes: not a tall tale

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Adiponectin and adiponectin receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Inflammation, stress, and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Relative hypoleptinemia in patients with type 1 and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Hepatic leptin signaling in obesity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Resistin: yet another adipokine tells us that men are not mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Recent concepts in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Dietary fat content modifies liver fat in overweight nondiabetic subjects.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Nuclear magnetic resonance studies of hepatic glucose metabolism in humans.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0190

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0190

1 reference

15 August 2017

1 reference

PubMed ID

16932311